Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 55 to 75 days old, inclusive on the day of first vaccination~* Born at full term of pregnancy (\> 37 weeks)~* Informed consent form signed by the parent(s) or the legal guardian~* Parents or the legal guardian able to read and write in the local language~* Parent(s) or the legal guardian able to attend all scheduled visits and to comply with the study procedures.~Exclusion Criteria:~* Presence of fever (defined as rectal body temperature ≥ 38.0°C) reported within the last 72 hours~* Moderate or severe acute illness with or without fever~* Participation in another clinical trial in the 30 days preceding first study vaccination~* Planned participation in another clinical trial during the present study period~* Received diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b or a pneumococcal vaccine separately or in combination prior to study vaccination~* Received any vaccination in the 30 days preceding the first study vaccination and/or is planning any vaccination within 6 weeks following any of the study vaccinations~* Congenital or acquired humoral/cellular immunodeficiency or immunosuppressive therapy such as long-term systemic corticosteroids therapy (≥ 2 mg/kg/day prednisone equivalent for ≥ 14 days) in the previous 30 days~* Systemic or local hypersensitivity to any of the study vaccine components (including neomycin, streptomycin, polymyxin B and formaldehyde)~* History of life-threatening reaction(s) (such as encephalopathy, Hypotonic-Hyporesponsive Episode, rectal body temperature ≥ 40.0°C, convulsions with or without fever) to any vaccine containing the same components as the study vaccines~* Blood or blood-derived products (immunoglobulins) received since birth~* Known Human immunodeficiency virus (HIV) seropositivity~* Known thrombocytopenia or other bleeding disorder contraindicating intramuscular vaccination~* History of encephalopathy, seizures or progressive, evolving or unstable neurological condition~* Clinically significant findings on review of systems that might interfere with study vaccination or which, in the opinion of the Investigator, would interfere with the evaluation of the study vaccine/objectives or pose a health risk to the subject.

- Gender: ALL
- Minimum Age: 55 Days
- Maximum Age: 75 Days
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): PEDIACEL co-administered with Prevenar
- Group 2 (Type: ACTIVE_COMPARATOR): Infanrix-IPV+Hib co-administered with Prevenar

Based on this trial design, predict the completion outcome and termination type (if applicable).